OM
AUTL

Opaleye Management’s Autolus Therapeutics AUTL Stock Holding History

Opaleye Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,112,918
Closed -$12.1M – 49
2021
Q1 		$12.1M Buy
+2,112,918
New +$15.6M 1.78% 16
2020
Q3 		– Sell
-60,000
Closed -$962K – 58
2020
Q2 		$962K Buy
+60,000
New +$665K 0.19% 45

Other funds holding AUTL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opaleye Management's AUTL Position: Q2 2021 in Review

Opaleye Management sold out of Autolus Therapeutics (AUTL) in Q2 2021, closing a stake of 2,112,918 shares — an estimated $12.1M sold.

Opaleye Management first reported a position in AUTL in Q2 2020 and held it in 2 quarters. The position peaked at $12.1M in Q1 2021. 69 funds tracked by Wall St. Rank hold AUTL as of Q2 2021.

  • Opaleye Management reported no remaining Autolus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Opaleye Management sold 2,112,918 Autolus Therapeutics shares in Q2 2021, an estimated $12.1M.
  • Opaleye Management first reported a position in Autolus Therapeutics in Q2 2020 and held it in 2 quarters.
  • Opaleye Management's Autolus Therapeutics position peaked at $12.1M in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2021.

Based on Opaleye Management's 13F filing for Q2 2021, filed 16 Aug 2021.